SuperGen operates a pharmaceutical compnay dedicated to the research and discovery of oncological drug therapy.
Business Model:
Revenue: $0
Employees: 51-200
Address:
City: Dublin
State: California
Zip:
Country: United States
SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. Products in Development MP-470—DNA Repair Suppressor: MP-470 is a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3. These protein kinase targets are involved in the growth and proliferation of cancer cells. MP-470 is also a suppressor of Rad51, a DNA repair protein which is involved in resistance to various chemotherapy agents and radiation. SuperGen, Inc. was founded in 1991.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 11/1999 | Venture Round | 1 | $7.6M |
Tako Ventures Tako Ventures |
10/2009 | Venture Round | $3M | 1/2008 | Venture Round | 1 | - |
New Enterprise Associates New Enterprise Associates |
1/2008 | Venture Round | 1 | - |
New Enterprise Associates New Enterprise Associates |
---|
Announced Date | Name | Price |
---|---|---|
4/2011 | Astex |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|